Faeth Therapeutics, Inc. (FTH)
Faeth Therapeutics, Inc. (FTH)
| Cash Flow | 2026-06-30 |
|---|---|
| Net loss | -186,243 |
| Stock-based compensation expense | 17,381 |
| Depreciation and amortization | 54 |
| Accretion on marketable securities | -1,126 |
| Non-cash lease expense | 770 |
| Amortization of financing lease right-of-use assets | 1 |
| Acquired in-process research and development from the acquisition of faeth therapeutics | -132,957 |
| Loss on asset disposal | 0 |
| Prepaid expenses | -10,360 |
| Other assets | -138 |
| Accounts payable and accrued liabilities | 247 |
| Compensation and employee benefits | -108 |
| Operating lease liabilities | -837 |
| Net cash used in operating activities | -26,406 |
| Purchases of property and equipment | 6 |
| Purchases of short-term investments | 158,560 |
| Maturities of short-term investments | 12,600 |
| Proceeds from sale of property and equipment | 0 |
| Net cash assumed in the acquisition of faeth therapeutics | -6,464 |
| Net cash (used in) provided by investing activities | -139,502 |
| Principal payments for financing leases | 80 |
| Proceeds from the sale of financing lease assets | 0 |
| Proceeds from issuance of series b redeemable convertible preferred stock | 200,000 |
| Issuance costs from the private placement issuance of series b redeemable convertible preferred stock | 16,908 |
| Payment of employee restricted stock tax withholdings | 0 |
| Employee stock purchase plan proceeds | 0 |
| Cash in lieu of fractional shares for reverse stock split | 0 |
| Exercise of options into common stock | 1,131 |
| Net cash provided by (used in) financing activities | 184,143 |
| Net increase in cash and cash equivalents | 18,235 |
| Cash and cash equivalents at beginning of period | 8,668 |
| Cash and cash equivalents at the end of period | 26,903 |